Close MenuClose
Close Menu

Daniel E . Hilleman, PharmD

Director, Continuing Education

Professor

Daniel Hilleman

Contact

School of Pharmacy and Health Professions
Pharmacy
Pharmacy Faculty
Pharmacy Practice
Faculty - Pharmacy, OT, PT
Continuing Education Faculty
HLSB - Hixson Lied Science Building

Daniel E . Hilleman, PharmD

Director, Continuing Education

Professor

Dr. Hilleman received his PharmD degree from Creighton University (Omaha, NE).  He completed a pre-doctoral research fellowship at the Poison Control Center at Children’s Hospital in Omaha.  Dr. Hilleman joined the faculty at the Creighton University School of Pharmacy in 1981. In 1985, Dr. Hilleman was appointed Director of Clinical Research at the Creighton University Cardiac Center. He held that position until 1993 when he was appointed Chair, Department of Pharmacy Practice, Creighton University School of Pharmacy and Health Professions. Dr. Hilleman stepped down as Chair in 2004. Dr. Hilleman then completed a one year sabbatical in information technology and distance education at the Center for Technology and Academic Advancement. After completing his sabbatical, Dr. Hilleman has been practicing in Cardiology and Critical Care at Creighton University’s teaching hospital. In 2012, Dr. Hilleman was appointed Director of Continuing Education for the Creighton University School of Pharmacy and Health Professions.
 
Dr. Hilleman is a Fellow of the American College of Clinical Pharmacy and a Fellow in the American College of Clinical Pharmacology. Dr. Hilleman chairs the University’s Research Conflict of Interest Committee.  He has served on the board of directors of the Nebraska Pharmacists Association and is a member of the National Lipid Association, the American Society of Hypertension, the American Pharmacists Association, the American College of Cardiology and the American Association of Colleges of Pharmacy.  He has authored over 200 peer reviewed publications and five book chapters.

Teaching Interests

  • Pharmacy

Research Focus

Cardiology
Critical Care

Department

Pharmacy Practice

Position

Professor

Books

  • Drug-induced Diseases: Prevention, Detection, and Management
    Malesker MA, Hilleman DE. Chapter 45: “Drug Induced SIADH and DI”; Drug-induced Diseases: Prevention, Detection and Management, 3rd Edition, Editors Tisdale J, Miller DA. ASHP Press; E5310; ISBN: 978-1-58528-531-0 97, 2018.
    3rd ed 2018
  • Springer Science+Business Media LLC
    Hilleman DE, Campbell J. Medication adherence in heart failure: In: The Kidney in Heart Failure; 2nd Edition. Edited by George Bakris, New York, New York: Springer Science, 2012. 2012

Articles

  • Current Problems in Cardiology (IF 4.19)
    Gill, G.S., Latif, A., Hilleman, D., Lavie, C., & Alla, V.M. (2021). Challenges in Implementing Evidence Based Cross-Disciplinary Therapies: Are Cardiovascular Specialists Ready to Claim SGLT-2 Inhibitors and GLP-1 Analogs? Current problems in cardiology, 100878 . 2021
  • Future Cardiology Journal
    Backes, J., & Hilleman, D. (2021). New and emerging lipid-lowering therapy. Future cardiology. 2021
  • Journal of the American Pharmacists Association
    Awadh, A.A., Hilleman, D., Knezevich, E.L., Malesker, M., & Gallagher, J.C. (2021). Vitamin D supplements: The pharmacists' perspective. Journal of the American Pharmacists Association : JAPhA. 2021
  • U.S. Pharmacist
    Backes JM, Hilleman DE. Lipid-lowering therapies: a review of current and future options. US Pharmacist 2021; February: www.uspharmacist.com. 2021
  • Pain Medicine
    Hilleman, D., Malesker, M., Aurit, S., & Morrow, L. (2020). Evidence for the Efficacy of an Opioid-Sparing Effect of Intravenous Acetaminophen in the Surgery Patient: A Systematic Review. Pain medicine. 2020
  • Advances in Therapy
    Hilleman, D., Wiggins, B., & Bottorff, M. (2020). A Response to: Letter to the Editor Regarding “Critical Differences Between Dietary Supplement and Prescription Omega-3 Fatty Acids: a Narrative Review”. Advances in Therapy, 37, 4046 - 4048.
    37, p. 4046-4048 2020
  • Advances in Therapy
    Hilleman, D., Wiggins, B., & Bottorff, M. (2020). Critical Differences Between Dietary Supplement and Prescription Omega-3 Fatty Acids: A Narrative Review. Advances in Therapy, 37, 656 - 670.
    37, p. 656-670 2020
  • Critical Care Medicine
    Malesker, M., Hilleman, D., Aurit, S., & Morrow, L. (2020). 916: A SYSTEMATIC REVIEW OF OPIOID-SPARING EFFECT OF INTRAVENOUS ACETAMINOPHEN IN ADULT SURGERY PATIENTS. Critical Care Medicine, 48, 437.
    48, p. 437 2020
  • P & T : a peer-reviewed journal for formulary management
    Wells, A., Woods, A., Hilleman, D., & Malesker, M. (2019). Alpha-1 Antitrypsin Replacement in Patients With COPD. P & T : a peer-reviewed journal for formulary management, 44 7, 412-415 .
    44 7, p. 412-415 2019
  • American Journal of Respiratory and Critical Care Medicine
    Malesker, M., Hilleman, D., & Morrow, L. (2019). Systematic Review of Intravenous Acetaminophen After Cardiac Surgery. 2019
  • Journal of Pharmacy Practice
    Hilleman, D., Teply, R.M., & Packard, K. (2019). Knowledge, Perceptions, and Patterns of Fish Oil Use in Cardiac Patients. Journal of Pharmacy Practice, 33, 580 - 585.
    33, p. 580-585 2019
  • Pharmacy and Therapeutics
    Hilleman DE, Malesker MA, Hannig D. Direct-acting oral anticoagulant use in special populations. P&T 2019; 44: 619-628
    44, p. 619-628 2019
  • Journal of Drug Assessment
    Schardt, G., Wolfe, M., Nolan, K., Murray, J., & Hilleman, D. (2018). ESC/EAS clinical guidance recommendations: impact on patient eligibility for PCSK9 inhibitor therapy. Journal of Drug Assessment, 7, 8 - 8.
    7, p. 8 2018
  • Journal of Drug Assessment
    Wolfe, M., Hilleman, D., Nolan, K., & Schardt, G. (2018). Impact of a dedicated medication access coordinator on PCSK9 inhibitor approval rates. Journal of Drug Assessment, 7, 9 - 9.
    7, p. 9 2018
  • Journal of Cardiac Failure
    Packard, K., & Hilleman, D. (2018). Initiation of Sacubitril/Valsartan Early after Heart Failure Decompensation. Journal of Cardiac Failure, 24.
    24 2018
  • American Journal of Health-System Pharmacy
    Malesker MA, Aurit S, Hilleman DE. Gastrointestinal tract recovery in patients undergoing selected surgical procedures. Am J Health-Sys Pharm 2018; 75 (Suppl 4): S87-S88.
    75, p. S87-S88 2018
  • Journal of Clinical Lipidology
    Hilleman, D., Teply, R.M., & Packard, K. (2018). Knowledge, Perceptions, and Patterns of Fish Oil “Use in Cardiac Patients' †. Journal of Clinical Lipidology, 12, 552-553.
    12, p. 552-553 2018
  • Specialty Pharmacy Times
    Hilleman DE, Malesker MA. A pharmacist’s review of hereditary angioedema management: diagnosis, treatment, and cost. Specialty Pharmacy Times 2018; 7: 40-52.
    7, p. 40-52 2018
  • treatment of depression in patients with concomitant cardiac disease
    Teply RM, Packard KA, White ND, Hilleman DE, DiNicolantonio JJ. Treatment of depression in patients with concomitant cardiac disease. Prog Cardiovasc Dis 2016; 58: 514-528. 2016
  • Clinical Lipidology
    Backes J, Anzalone D, Hilleman D, Catini J. The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia. Lipid in Health and Disease 2016; 15: 118-128. 2016
  • American Journal of Managed Care
    Hilleman DE, Smer A. Prescription omega-3 fatty acid products and dietary supplements are not interchangeable. Managed Care 2016; 25: 46-52. 2016
  • LipidSpin
    Mason RP, Hilleman DE. Omega-3 fatty acid fish oil dietary supplements for disease management: are they appropriate for patients? Lipid Spin 2016; 14: 29-31.
    14, p. 29-31 2016
  • Journal of Surgery
    Malesker MA, Bruckner AL, Loggie B, Hilleman DE. IV acetaminophen: assessment of medication utilization evaluation data in peri-operative pain management. J Surgery 2015; 10:6-10.
    10, p. 6-10 2015
  • Nebraska Mortar and Pestle
    Hilleman DE, Burns TL. Update on recently approved pharmacotherapy in the management of obesity. Nebraska Mortar & Pestle 2015; Mar/Apr: 19-27., p. 19-27 2015
  • Annals of Pharmacotherapy
    Au, T. H., Bruckner, A., Mohiuddin, S. M., Hilleman, D. E. The prevention of contrast-induced nephropathy
    48, p. 1332-1342 2014
  • Cardiovascular Therapeutics
    Ling, Hua, Burns, Tammy L., Hilleman, Daniel E. An Update on the Clinical Development of Proprotein Convertase Subtilisin Kexin 9 Inhibitors, Novel Therapeutic Agents for Lowering Low-Density Lipoprotein Cholesterol
    32, p. 82-88 2014
  • Cardiology Research
    Campbell, JA, Teply, R., Mooss, AN, Hilleman, DE Impact of grapefruit juice on the antiplatelet activity of loading and maintenance doses of clopidogrel in healthy volunteers.
    5, p. 32-38 2014
  • Clinical Medicine Insights: Cardiology
    Hilleman, DE, Malesker, MA Potenial benefits of icosapent ethyl on the lipid profile: case studies.
    8, p. 13-15 2014
  • Journal of Managed Care Pharmacy : JMCP
    Hilleman, D. E. Adherence and health care costs with single-pill fixed-dose combinations in hypertension management
    20, p. 93-100 2014
  • Pharmacotherapy
    Au TH, Bruckner A, Mohiuddin SM, Hilleman DE. The prevention of contrast-induced nephropathy. Annals of Pharmacotherapy 2014; 48: 971-976.
    48, p. 971-976 2014
  • Cardiology Research
    Gorthi J, Hunter CB, Mooss AN, All VM, Hilleman DE. Reducing heart failure readmissions: a systematic review of disease management programs. Cardiol Res 2014; 5: 126-138.
    5, p. 126-138 2014
  • Pharmacy Education
    Packard K, Gibu M, Teply R, Hilleman D, Qi Y. Pharmacy student intervention acceptance on a cardiology rotation. Pharmacy Education 2014; 14: 64-69.
    14, p. 64-69 2014
  • Pharmacotherapy
    Ling, Hua, Lenz, Thomas L., Burns, Tammy L., Hilleman, Daniel E. Reducing the Risk of Obesity: Defining the Role of Weight Loss Drugs
    33, p. 1308-1321 2013
  • American Journal of Cardiovascular Drugs
    Ling, Hua, Packard, Kathleen A., Burns, Tammy L., Hilleman, Daniel E. Impact of Ranolazine on Clinical Outcomes and Healthcare Resource Utilization in Patients with Refractory Angina Pectoris
    13, p. 407-412 2013
  • Clinical Lipidology
    Hilleman, Daniel E. Optimal use of lipid-altering therapy: guidelines versus evidence
    8, p. 269-272 2013
  • World Medical & Health Policy
    Burns, Tammy L., Ruckman, Jilyan A., Ling, Hua, Washington-Krauth, Shavonne M., Hilleman, Daniel E., Mohiuddin, Syed M. Current State of United States Tobacco Control Initiatives
    5, p. 245-259 2013
  • Cardiology Research
    Ling H, Luoma JT, Hilleman DE. A review of currently available fenofibrate and fenofibric acid formulations. Cardiol Res 2013: 4: 47-55.
    4, p. 47-55 2013
  • Pharmacy and Therapeutics
    Bradberry JC, Hilleman DE. Omega-3 fatty acids: overview of current therapies. P & T 2013: 38: 681-691.
    38, p. 681-691 2013
  • Journal of Critical Care
    Malesker, Mark A., Hilleman, Daniel E. Intravenous labetalol compared with intravenous nicardipine in the management of hypertension in critically Ill patients
    27, p. 528.e7-528.e14 2012
  • Cardiology Research
    Hawkins EB, Ling H, Burns TL, Mooss AN, Hilleman DE. Aliskiren in patients failing to achieve blood pressure targets with angiotensin converting enzyme inhibitors or angiotensin receptor blockers. Cardiology Res 2012; 3:147-153.
    3, p. 147-153 2012
  • American Journal of Pharmacy Benefits
    Hilleman DE. New oral anticoagulants for stroke prevention in atrial fibrillation. Am J Pharmacy Benefits 2012; 4: 356-362.
    4, p. 356-362 2012
  • Postgraduate Medicine
    Ling H, Burns TL, Hilleman DE. Novel strategies for managing dyslipidemia: treatment beyond statins. Postgraduate Medicine 2012; 124: 43-54.
    124, p. 43-54 2012
  • American Journal of Emergency Medicine
    Peacock WF 4th, Hilleman DE, Levy PD, Rhoney DH, Varon J. A systematic review of nicardipine vs labetalol for the management of hypertensive crises. Am J Emergency Med 2012; 30: 981-983.
    30, p. 981-983 2012
  • American Journal of Therapeutics
    Deshmukh A, Hilleman D, Del Core M, Nair CK. Antithrombotic regimens in patients with indication for long-term anticoagulation undergoing coronary interventions – systematic analysis, review of literature, and implications on management. Am J Ther 2011; 18: 203-210.
    18, p. 203-210 2011
  • International journal of chronic obstructive pulmonary disease
    Dewan NA, Rice KL, Caldwell M, Hilleman DE. Economic evaluation of a disease management program for chronic obstructive pulmonary disease. J Chronic Pulm Dis 2011; 8: 153-159.
    8, p. 153-159 2011
  • Coronary Artery Diesease
    Go J, Narmi A, Sype J, Mooss AN, Hilleman DE. Impact of renal dysfunction on the prognostic value of the TIMI risk score in patients with non-ST elevation acute coronary syndrome. Coronary Artery Disease 2011; 22: 411-415.
    22, p. 411-415 2011
  • Pharmacotherapy
    Hilleman DE, Campbell J. Efficacy, safety, and cost of thrombolytic agents for the management of dysfunctional hemodialysis catheters: a systematic review. Pharmacotherapy 2011; 31: 1031-1040.
    31, p. 1031-1040 2011
  • Seminars in thrombosis and hemostasis
    Campbell, J., Hilleman, D. Recombinant Peptides in Thrombolysis
    36, p. 529-536 2010
  • Pharmacotherapy
    Packard, K. A., Hilleman, D. E., Davis, Estella M. Pharmacologic prophylaxis of postoperative atrial fibrillation in patients undergoing cardiac surgery: beyond beta-blockers
    30, p. 749 2010
  • Managed Care
    Malesker, M. A., Hilleman, D. E. Comparison of amlodipine/valsartan fixed-dose combination therapy and conventional therapy
    19, p. 36-42 2010
  • Formulary
    Campbell, Jennifer, Hilleman, Daniel Reducing cardiovascular risk in patients with type 2 diabetes: management of dyslipidemia
    45, p. 124-134 2010
  • Expert Opinion on Pharmacotherapy
    Schima, S. M., Maciejewski, S. R., Hilleman, D. E., Williams, M. A., Mohiuddin, S. M. Fibrate therapy in the management of dyslipidemias, alone and in combination with statins: role of delayed-release fenofibric acid
    11, p. 731-738 2010
  • Journal of Asthma and Allergy
    Teply, Robyn M., Campbell, J., Hilleman, D. Current trends in the treatment of asthma: focus on simultaneous administration of salmeterol/fluticasone
    3, p. 1-8 2010
  • Chest
    Hilleman, D. E., Dewan, N., Malesker, M., Friedman, M. Pharmacoeconomic evaluation of COPD
    136, p. e30 2009
  • International journal of chronic obstructive pulmonary disease
    Hilleman, D. E., Malesker, M. A., Morrow, L. E., Schuller, D. A systematic review of the cardiovascular risk of inhaled anticholinergics in patients with COPD
    4, p. 253-263 2009
  • Pharmacotherapy
    Maciejewski, S., Hilleman, D. Effettiveness of a fenofibrate 145-mg nanoparticle tablet formulation compared with the standard 160-mg tablet in patients with coronary heart disease and dyslipidemia
    28, p. 570-575 2008
  • Journal of Vascular and Interventional Radiology
    Hilleman, D. E., Razavi, M. K. Clinical and economic evaluation of the Trellis-8 infusion catheter for deep vein thrombosis
    19, p. 377-383 2008
  • Consultant Pharmacist
    Coover, K., Ryan-Haddad, Ann, Faulkner, M., Hilleman, Daniel E. Prevalence, treatment and control of hypertension in residents of skilled nursing facilities
    23, p. 317-323 2008
  • Pharmacotherapy
    Hilleman, Daniel E., Tsikouris, James P., Seales, Allen, Marmur, Jonathan D. Fibrinolytic Agents for the Management of ST-Segment Elevation Myocardial Infarction
    27, p. 1558-1570 2007
  • American Journal of Critical Care
    Malesker, M. A., Foral, P. A., McPhillips, A. C., Christensen, K. J., Chang, J. A., Hilleman, D. E. An efficiency evaluation of protocols for tight glycemic control in intensive care units
    16, p. 589-598 2007
  • Pharmacotherapy
    Burns, T., Madejewski, S. R., Hamilton, W. R., Zheng, M., Mooss, A. N., Hilleman, D. E. Effect of omega-3 fatty acid supplementation on the arachidonic acid: Eicosapentaenoic acid ratio
    27, p. 633-638 2007
  • Pharmacotherapy
    Buckley, M. S., Nolan, P. E., Slack, M. K., Tisdale, J. E., Hilleman, D. E., Copeland, J. G. Amiodarone prophylaxis for atrial fibrillation after cardiac surgery: Meta-analysis of dose response and timing of initiation
    27, p. 360-368 2007
  • Biodrugs
    Simpson, D., Siddiqui, M. A. A., Scott, L. J., Hilleman, D. E. Spotlight on reteplase in thrombotic occlusive disorders
    21, p. 65-68 2007
  • Critical Care Medicine
    Van den Berghe, G., Wouters, P. J., Kesteloot, K., Hilleman, D. E. Analysis of healthcare resource utilization with intensive insulin therapy in critically ill patients
    34, p. 612-616 2006
  • Pharmacotherapy
    Maciejewski, S., Mohiuddin, S. M., Packard, K. A., Mooss, A. N., Reyes, A. P., Aryana, A., Hilleman, D. E. Randomized, double-blind, crossover comparison of amlodipine and valsartan in African- Americans with hypertension using 24-hour ambulatory blood pressure monitoring
    26, p. 889-895 2006
  • International Journal of Cardiology
    Hilleman, D. E. Cost considerations with tight glycemic control in the acute care setting
    18, p. 359-365 2006
  • Pharmacotherapy
    Burns, T. L., Mooss, A. N., Hilleman, D. E. Antiplatelet drug resistance: Not ready for prime time
    25, p. 1621-1628 2005
  • American Journal of Cardiovascular Drugs
    Hilleman, D. E., Hunter, C. B., Mohiuddin, S. M., Maciejewski, S. Creighton University Cardiac Center, Omaha, NE, USA; Pharmacological management of atrial fibrillation following cardiac surgery
    5, p. 361-369 2005
  • Journal of Managed Care Pharmacy
    Hilleman, D. E. New treatment options in COPD
    11, p. S12-S19 2005
  • Ethnicity and Disease
    Packard, K. A., Majeed, F., Mohiuddin, S. M., Mooss, A. N., Hilleman, D. E., Arouni, A. J. Low high-density lipoprotein cholesterol is associated with impaired endothelial function in Asian Indians
    15, p. 555-561 2005
  • Pharmacotherapy
    Lenz, T. L., Foral, P. A., Malesker, M. A., Hunter, C. B., Hilleman, D. E. Impact of nesiritide on health care resource utilization and complications in patients with decompensated heart failure
    24, p. 1137-1146 2004
  • Pharmacotherapy
    Hilleman, D. E., Faulkner, M. A., Monaghan, M. S. Cost of a pharmacist-directed intervention to increase treatment of hypercholesterolemia
    24, p. 1077-1083 2004
  • Pharmacotherapy
    Hilleman, D. E., Lucas, B. D. Angiotensin-converting enzyme inhibitors and stroke risk: Benefit beyond blood pressure reduction?
    24, p. 1064-1076 2004
  • Journal of Vascular Surgery
    Sarac, T. P., Hilleman, D., Arko, F. R., Zarins, C. K., Ouriel, K. Clinical and economic evaluation of the trellis thrombectomy device for arterial occlusions: Preliminary analysis
    39, p. 556-559 2004
  • Chest
    Foral, P. A., Malesker, M. A., Huerta, G., Hilleman, D. E. Nebulized opioids use in COPD
    125, p. 691-694 2004
  • Pharmacotherapy
    Faulkner, M. A., Hilleman, D. E. Pharmacologic treatment of chronic obstructive pulmonary disease: Past, present, and future
    23, p. 1300-1315 2003
  • Formulary
    Hilleman, D. E. Reducing cardiovascular risk in patients with type 2 diabetes: Management of dyslipidemia
    38, p. 478-497 2003
  • Pharmacotherapy
    Hilleman, D. E., Spinler, S. A. Conversion of recent-onset atrial fibrillation with intravenous amiodarone: A meta-analysis of randomized controlled trials
    22, p. 66-74 2002
  • Blood pressure monitoring
    Hilleman, D. E. Pharmacoeconomics of combination antihypertensive therapy
    6, p. S31-S36 2001
  • Chest
    Nair, C. K., Khan, I. A., Esterbrooks, D. J., Ryschon, K. L., Hilleman, D. E. Diagnostic and prognostic value of holter-detected ST-segment deviation in unselected patients with chest pain referred for coronary angiography - A long-term follow-up analysis
    120, p. 834-839 2001
  • Pharmacotherapy
    Faulkner, M. A., Hilleman, D. E., Destache, C. J., Mooss, A. N. Potential influence of timing of low-density lipoprotein cholesterol evaluation in patients with acute coronary syndrome
    21, p. 1055-1060 2001
  • Journal of human hypertension
    Hilleman, D. E., Reyes, A. P., Wurdeman, R. L., Faulkner, M. Efficacy and safety of a therapeutic interchange from high-dose calcium channel blockers to a fixed-dose combination of amlodipine/benazepril in patients with moderate-to-severe hypertension
    15, p. 559-565 2001
  • Pharmacotherapy
    Lenz, T. L., Wurdeman, R. L., Hilleman, D. E. Comparison of 24-hour blood pressure profiles in patients with hypertension who were switched from amlodipine to nisoldipine
    21, p. 898-903 2001
  • Annals of Pharmacotherapy
    Spinler, S. A., Hilleman, D. E., Cheng, J. W.M., Howard, P. A., Mauro, V. F., Lopez, L. M., Munger, M. A., Gardner, S. F., Nappi, J. M. New recommendations from the 1999 American College of Cardiology/American Heart Association acute myocardial infarction guidelines
    35, p. 589-617 2001
  • Pharmacotherapy
    Hilleman, D. E., Bauman, J. L. Role of antiarrhythmic therapy in patients at risk for sudden cardiac death: An evidence-based review
    21, p. 556-575 2001
  • Pharmacotherapy
    Hilleman, D. E., Wurdeman, R. L., Lenz, T. L. Therapeutic change of HMG-CoA reductase inhibitors in patients with coronary artery disease
    21, p. 410-415 2001
  • Pharmacoeconomics
    Friedman, M., Hilleman, D. E. Economic burden of chronic obstructive pulmonary disease - Impact of new treatment options
    19, p. 245-254 2001
  • Chest
    Hilleman, D. E., Dewan, N., Malesker, M., Friedman, M. Pharmacoeconomic evaluation of COPD
    118, p. 1278-1285 2000
  • Annals of Pharmacotherapy
    Lenz, T. L., Hilleman, D. E. Aggrenox: A fixed-dose combination of aspirin and dipyridamole
    34, p. 1283-1290 2000
  • Drugs of Today
    Lenz, T. L., Hilleman, D. E. Dofetilide: A new antiarrhythmic agent approved for conversion and/or maintenance of atrial fibrillation/atrial flutter
    36, p. 759-771 2000
  • American Journal of Health-System Pharmacy
    Hilleman, D. E. Role of angiotensin-converting-enzyme inhibitors in the treatment of hypertension
    57, p. S8-S11 2000
  • Formulary
    Hilleman, D. E. New approaches to the management of AMI: Fibrinolysis plus GP IIb/IIIa receptor blockade
    35, p. 738-751 2000
  • Pharmacotherapy
    Hilleman, D. E., Heineman, S. M., Foral, P. A. Pharmacoeconomic assessment of HMG-CoA reductase inhibitor therapy: An analysis based on the CURVES study
    20, p. 819-822 2000
  • American Heart Journal
    Mooss, A. N., Wurdeman, R. L., Mohiuddin, S. M., Reyes, A. P., Sugimoto, J. T., Scott, W., Hilleman, D. E., Seyedroudbari, A. Esmolol versus diltiazem in the treatment of postoperative atrial fibrillation/atrial flutter after open heart surgery
    140, p. 176-180 2000
  • Pharmacotherapy
    Skrabal, M. Z., Stading, J. A., Behmer-Miller, K. A., Hilleman, D. E. Advances in the treatment of congestive heart failure: New approaches for an old disease
    20, p. 787-804 2000
  • Pharmacotherapy
    Lenz, T. L., Hilleman, D. E. Dofetilide, a new class III antiarrhythmic agent
    20, p. 776-786 2000
  • Journal of Thrombosis and Thrombolysis
    Seyedroudbari, A., Kessler, E. R., Mooss, A. N., Wurdeman, R. L., Bala, M., Hilleman, D. E. Time to treatment and cost of thrombolysis: A multicenter comparison of tPA and rPA
    9, p. 303-308 2000
  • Pharmacotherapy
    Faulkner, M. A., Wadibia, E. C., Lucas, B. D., Hilleman, D. E. Impact of pharmacy counseling on compliance and effectiveness of combination lipid-lowering therapy in patients undergoing coronary artery revascularization: A randomized, controlled trial
    20, p. 410-416 2000
  • convenient care
    Hilleman DE, Mohiuddin SM. Collaborative obesity management: advanced practice clinicians working with patients. Convenient Care 2015; 9: 20-21.
  • Clinical Lipidology
    Mason RP, Hilleman DE. Omega-3 fatty acid fish oil dietary supplements for disease management: are they appropriate for patients? Lipid Spin 2016; 14: 29-31.

Publications

  • Pharmacotherapy
    Malesker MA, Dehal N, Hilleman DE. Opioid-sparing effect of liposomal bupivacaine in total knee arthroplasty patients: a systematic analysis of randomized controlled trials. Pharmacotherapy 2020; 3:1225 (Abstract). 2020
  • Journal of Managed Care & Specialty Pharmacy
    Hilleman DE, Malesker MA. Utilization of dabigatran in patients with atrial fibrillation: impact of the ACCP guidelines and the SAMe-TT2R2 score. J Man Care Pharm 2015; 21: S47.
    21, p. S47 2015
  • Deshmukh A, Patel N, Azzouz M, Haroon S, Hilleman DK, Kaushik M, White M, DelCore M, Mooss A, Esterbrooks D, Lanspa T. Efficacy and safety of transradial approach to renal artery interventions. J Am Coll Cardiol Intv 2014; 7(2S): S38.
    7(2S), p. S38 2014
  • Deshmukh A, Patel N, Kandasamy V, Hilleman DE, et al. Radial versus femoral approach to high speed rotational atherectomy. J Am Coll Cardiol Intv 2014; 7: S29-S30.
    7, p. s29-s30 2014
  • Chest
    Au T, Malesker M, Hilleman DE, et al. A retrospective analysis of dexmedetomidine use for alcohol withdrawal syndrome in critical care patients. Chest 2014; 146: 225A.
    146, p. 225A 2014
  • Critical Care Medicine
    Malesker MA, Hawkins E, Hilleman DE, Morrow LE. Intermittent bolus dosing vs continuous infusion furosemide in ICU patients with diuretic resistance. Crit Care Med 2013; 41:3 (abstract).
    41, p. 3 2013
  • Hilleman D, Ling H, Luoma J. A review and comparison of fenofibrate and fenofibric acid formulations available in the United States. American Academy of Nurse Practitioners; June 2012; Orlando, FL. Abstract 24. 2012
  • Chest
    Hawkins E, Malesker M, Hilleman D, Morrow L. A retrospective analysis of intermittent bolus dosing versus continuous infusion dosing of furosemide in critical care patients with diuretic resistance. Chest 2012; 142: 402A.
    142, p. 402A 2012
  • Pharmacotherapy
    Hawkins E, Ling H, Burns T, Hilleman D. Perceptions, knowledge, and patterns of use of “fish oil” products in cardiac patients. Pharmacotherapy, 2012; 32: e184.
    32, p. e184 2012
  • Pharmacotherapy
    Hawkins E, Ling H, Burns T, Mooss A, Hilleman D. Aliskiren in patients failing to achieve blood pressure targets with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. Pharmacotherapy 2012; 32: e184.
    32, p. e184 2012
  • Chest
    Hawkins E, Malesker M, Hilleman D, Morrow L. A retrospective analysis of intermittent bolus dosing versus continuous infusion dosing of furosemide in critical care patients with diuretic resistance. Chest 2012; 142: 402A.
    142, p. 402A 2012
  • Kaushik M, Deshmukh A, Pandva J, Hilleman D, Esterbrooks D, Mohiuddin S. Echocardiographic correlates of persistent ST-elevation on ECG in STEMI patients undergoing percutaneous coronary intervention. JACC 2012; 60 (suppl B): B148.
    60, p. B148 2012
  • Chest
    Malesker, MA, Boldt D, Ling H, Burns T, Hilleman DE. Impact of the ACCP antithrombotic guidelines on potential utilization of dabigatran in patients with atrial fibrillation. Chest 2013; 144: 161A.
    144, p. 161A 2012

General

  • Cardiovascular Therapeutics
    Packard KA, Hilleman DE. Adherence to therapies for secondary prevention of cardiovascular disease: focus on aspirin. Cardiovascular Ther 2016; 34: 415-422. 2016